Global pharmaceutical company Alexion Pharmaceuticals continues to expand globally with the announcement that a new office and laboratory facility will be established in Dublin, providing global supply chain and quality operations.
Work completed at this Dublin facility will serve patients in 50 countries with rare life-threatening disorders and will also manage the supply of new therapies from Alexion, following regulatory approvals, over the next several years.
Alexion is now seeking about 50 employees for a range of initial positions in supply chain, quality assurance, quality control and logistics and this recruitment drive is expected to be completed by the end of this year.
“Ireland’s Government and universities have an unparallelled commitment and robust partnerships with regard to education and training for pharmaceutical manufacturing, quality assurance, quality control and supply logistics. For these reasons, as we continue to expand our global supply chain and quality team, we are very pleased to come to Ireland for its highly skilled and educated workforce,” said Stephen Squinto, PhD, executive vice-president and chief global operations officer at Alexion.
This announcement is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland. With the decision by Alexion to establish a base in Ireland, IDA Ireland has now attracted seven of the world’s top 10 global biopharma companies to its shores.
“Biopharma companies like Alexion are currently developing the next generation of medicines,” said IDA Ireland CEO Barry O’Leary. “Biopharma differs from more traditional pharmaceutical methods in that it derives the final product from living organisms. This activity represents the cutting-edge of innovative drug development and requires skilled, highly qualified staff.”
